SAN FRANCISCO, CA--(Marketwired - Jun 25, 2015) - What a difference just nine months can make. NovaBay Pharmaceuticals Inc. (NYSE MKT: NBY) has a materially derisked business strategy with new products coming rapidly to market, big-time distribution partners in place and new shareholders embracing the stock following a drug trial disappointment in mid-August 2014. In this interview with The Life Sciences Report, company founder, President and CEO Dr. Ramin "Ron" Najafi talks about the turnaround and how he is steering the product portfolio toward a hockey-stick sales growth curve.

The Life Sciences Report: Ron, NovaBay Pharmaceuticals Inc. looks like a turnaround story, with shares up more than 45% over the past three months. This follows disappointing results from a Phase 2b trial in viral conjunctivitis last August, a program that NovaBay has now set aside. Describe your new focus.

Ron Najafi: Our strategy, which we introduced last January, is to focus on the eye care market, and we are very excited about the commercialization of Avenova™, our product that manages the unmet medical needs of blepharitis and meibomian gland dysfunction, or dry eye syndrome.

Some background: When our NeutroPhase® product for chronic non-healing wounds became available to clinicians, my sister, who is an ophthalmologist, cataract surgeon and glaucoma specialist, took it upon herself to use NeutroPhase as a lid and lash hygiene product. NeutroPhase is formulated with Neutrox™, our pure hypochlorous acid, which mimics a naturally occurring substance produced by white blood cells to fight microbial invaders. She saw the potential of this product to...

Continue reading this interview with Dr. Ramin Najafi: A Clear Vision for a Turnaround: Ron Najafi of NovaBay Pharmaceuticals

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.


Novabay Pharmaceuticals Inc. paid The Life Sciences Report to conduct, produce and distribute the interview. Dr. Ramin Najafi had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Dr. Ramin Najafi and not of The Life Sciences Report or its officers. 

Contact Information:

Carrie Beal Amaro
Phone: (707)283-0676